HONG KONG, Dec. 22, 2025 /PRNewswire/ -- On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited ("TVB"), was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with the highest accolade, the "Outstanding ESG Award", as well as awards for "Best in ESG Practices" and "Best in ESG Report".

Mr. Wong Wai Lun, Michael, GBS, JP, Deputy Financial Secretary of the Government of the Hong Kong Special Administrative Region (SAR), Mr. Siu Sai Wo, General Manager (Business Operations) of TVB and Dr. Lawrence Cheung Chi-chong, Chief Technology Officer of Hong Kong Productivity Council served as officiating guests at the awards ceremony and jointly presented the "Outstanding ESG Award" to Fosun International.

TVB pointed out that Fosun International's recognition with the "Outstanding ESG Award", "Best in ESG Practices" and "Best in ESG Report" is well-deserved. After more than 30 years of development, Fosun has developed into a large global company with operations spanning healthcare, tourism, consumption, and insurance. With a robust global industrial ecosystem, Fosun operates responsibly in over 40 countries and regions, actively contributing to public welfare and creating sustainable value worldwide.

TVB highlighted that the awards recognize Fosun International's outstanding performance in environmental, social, and governance (ESG) and sustainability, while affirming its excellent achievements in ESG over the past year. Each award is presented to the top three scorers in their respective categories, with organizations excelling in both "ESG Practices" and "ESG Report" eligible for the highest accolade, the "Outstanding ESG Award".

In addition to Fosun International, other recipients of TVB's highest accolade, the "Outstanding ESG Award", are all organizations that have demonstrated excellence in ESG. These include government statutory bodies, major public utilities, and well-known companies such as the Airport Authority Hong Kong, MTR Corporation, Schneider Electric, China State Construction Development Holdings Limited, and Riskory Consultancy Limited.

Ms. Angel Sze, Company Secretary and Head of ESG Management Committee of Fosun International, accepted the "Outstanding ESG Award" on behalf of the company and subsequently joined representatives from other award-winning organizations in a panel discussion to share Fosun International's ESG practices and achievements.

Driven by innovation, committed to social contribution

During the discussion, Angel Sze remarked, "Fosun remains committed to innovation-driven development and globalization. Since its establishment, Fosun has stayed true to its original aspiration of 'Contribution to Society', striving to create positive societal impact through its operations. Taking our Health segment as an example, we target original innovation to address unmet clinical needs. By continuously strengthening our independent R&D and innovation capabilities, we strive to deliver higher-quality, more accessible, and more affordable medicines and services to patients."

Fosun adheres to an innovation-driven strategy, and the anticancer drugs developed by its Health segment have widely benefited cancer patients. Among them, HANSIZHUANG, an innovative anti-PD-1 monoclonal antibody independently developed by Fosun, is the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). To date, it has been approved for marketing in nearly 40 countries and regions, including China, the European Union, the United Kingdom, Singapore, and India.

Since the beginning of this year, Fosun has achieved multiple breakthroughs in the field of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as a potential highly effective and safe broad-spectrum anticancer drug.

On 7 December, the National Healthcare Security Administration (NHSA) and the Ministry of Human Resources and Social Security (MOHRSS) released the 2025 national medical insurance drug list, which includes multiple marketed products from Fosun Pharma. Moreover, the highly anticipated inaugural edition of the commercial insurance innovative drug list was unveiled, featuring Fosun Pharma's CAR-T cell therapy Yi Kai Da (ejilunsai injection). The successful inclusion of innovative drugs underscores national support for pharmaceutical innovation and paves the way for market promotion and patient access.

Fosun's innovation capabilities have also received high recognition from global pharmaceutical companies. On 9 December, Fosun Pharma announced that its subsidiary had entered into a license agreement with Pfizer, granting Pfizer exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonists, including YP05002, and any products containing such oral small molecule GLP-1R agonists as an active ingredient.

At the same time, Fosun actively integrates global resources to accelerate the introduction of cutting-edge medical technologies in China, enhancing the accessibility and affordability of medical technologies. By the end of September 2025, over 480 Da Vinci surgical systems had been installed in more than 370 hospitals across the Chinese mainland, Hong Kong SAR, and Macau SAR, collectively serving over 810,000 patients.

Centering on "Health" as a global public issue, Fosun launched the Rural Doctors Program in 2017. Since its launch, the Program has supported 25,000 rural doctors and benefited 3 million rural families. It was honored as one of the United Nations Global Compact's "20 Cases of Private Sector's Sustainable Development in China for 20 Years", earning international recognition as a model for empowering rural healthcare.

Actively responding to climate change and attaching great importance to biodiversity conservation

With climate change being one of the most severe long-term risks, Fosun recognizes the importance of global cooperation to tackle this challenge. Fosun remains committed to advancing China's "dual carbon" goals by promoting carbon neutrality and energy conservation and emission reduction. In 2021, Fosun made a commitment to society – "strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050". Fosun has formulated strategies for climate change mitigation and adaptation to align with the 1.5°C temperature control target set in the Paris Agreement.

The Group also actively encourages its member companies to carry out climate actions. In 2024, the Bund Finance Center (BFC), the Group's main office location in Shanghai and a landmark in Shanghai, was successfully included in Shanghai's first batch of carbon peaking and carbon neutrality pilot demonstration projects, becoming the only large-scale commercial complex exceeding 200,000 square meters on the list.

In 2024, Fidelidade, Fosun's insurance company in Portugal, established the Impact Center For Climate Change (ICCC), a knowledge center dedicated to climate change research. Through collaborations with external entities, including universities, research centers, and public institutions, it provides scientific insights on the impacts of climate change on society, particularly in the insurance industry.

In addition to actively addressing climate change, Fosun also places great importance on biodiversity conservation. Since 2018, the Lost Chambers Aquarium at Atlantis Sanya, a subsidiary of Fosun Tourism Group (FTG), has been dedicated to rescuing and rehabilitating sea turtles in Hainan Province and its surrounding waters. As of 2024, the aquarium had rescued 24 sea turtles and held 6 sea turtle release events since its opening, returning 10 rehabilitated turtles to the ocean.

On 28 November, FTG hosted "Fosun Holiday Horizon 2026" at Atlantis Sanya, where it signed a partnership agreement with the Nanjing Institute of Environmental Sciences (NIES) of the Ministry of Ecology and Environment (MEE). The two parties will incorporate biodiversity conservation and habitat creation into Club Med resorts, jointly developing China's first "biodiversity resort" centered on the concept of "harmonious coexistence between humans and nature".

Empowering a sustainable future through globalization and innovation

Looking ahead, Fosun will remain focused on its core businesses, step up innovation efforts, and firmly advance its globalization strategy, creating greater value for shareholders, employees and society. At the same time, Fosun will continue to closely follow global sustainability trends, continuously refine its ESG management, actively respond to national strategies, ensure information security, promote technology innovation, implement "dual carbon" goals, participate in public welfare undertakings, and protect employees' rights and interests. Leveraging the resources and advantages of its global industrial ecosystem, Fosun endeavors to make a greater impact on sustainable development and continuously contribute to a better world.

香港2025年12月22日 /美通社/ -- 2025年12月19日，由電視廣播有限公司（以下簡稱「TVB」）主辦的TVB環境、社會及管治大獎2025頒獎典禮在香港會議展覽中心舉行，復星國際榮獲TVB頒發最高級別的「ESG年度卓越大獎」，另同時獲頒「ESG最佳表現大獎」及「ESG最佳報告大獎」。

香港特區財政司副司長黃偉綸先生，GBS，JP，電視廣播有限公司總經理（商務營運）蕭世和先生及香港生產力促進局首席技術總監張梓昌博士擔任此次頒獎主禮嘉賓，並一同頒發「ESG年度卓越大獎」予復星國際。

TVB指出，復星國際榮獲「ESG年度卓越大獎」、「ESG最佳表現大獎」及「ESG最佳報告大獎」三大獎項乃實至名歸。復星經過30多年發展，已發展成為一家全球化的大型產業集團，業務覆蓋醫療、旅遊、消費及保險等領域。憑借完善的全球產業生態佈局，復星在超過40個國家和地區負責任運營，積極助力全球民生福祉與可持續價值創造。

TVB指出，本次獎項旨在表彰復星國際在環境、社會及管治（ESG）及可持續發展方面的卓越表現，並肯定其過去一年在ESG領域的優秀實踐成果。每個獎項均由各組別中評分最高的三家機構獲得，而在「ESG表現」及「ESG報告」兩方面同時達到最佳水平的機構，更可獲頒最高級別的「ESG年度卓越大獎」。

此次與復星國際一同榮獲TVB最高級別「ESG年度卓越大獎」的單位，均是在ESG領域表現突出的機構，涵蓋政府法定機構、主要公共事業單位及知名企業，包括香港機場管理局、港鐵公司、施耐德電氣、中國建築興業集團、Riskory Consultancy Limited。

復星國際公司秘書兼ESG管理委員會負責人史美明女士代表公司上台領獎，並在隨後與其他榮獲「ESG年度卓越大獎」的單位代表共同參與研討交流，分享復星國際在ESG領域的實踐經驗與成果。

創新驅動，積極回饋社會

史美明在交流時表示：「復星一直堅持創新驅動和全球化發展，創業至今，始終堅持『助天下』的初心，致力通過業務活動為社會帶來積極影響。以我們健康業務為例，我們以源頭創新為目標，聚焦未滿足的臨床需求，通過持續增強自主研發創新能力，為患者提供更優質、更可及、更可負擔的藥品和服務。」

復星堅持創新驅動，旗下健康產業研發的抗癌藥物，廣泛惠及癌症患者。其中，自主研發的創新型抗PD-1單抗H藥漢斯狀，是全球首個獲批用於一線治療小細胞肺癌的抗PD-1單抗。截至目前，H藥已在中國、歐盟、英國、新加坡、印度等近40個國家和地區獲批上市。

今年以來，復星在創新藥領域實現多點破局。HLX43是一款靶向PD-L1的抗體偶聯藥物（ADC），正在中、美、澳等國家開展非小細胞肺癌、胸腺癌等實體瘤的臨床研究。目前，全球範圍內尚無PD-L1 ADC獲批上市，HLX43有潛力成為高效、安全的「廣譜抗癌藥」。

12月7日，國家醫保局、人力資源社會保障部發佈2025年國家醫保目錄，復星醫藥旗下多款已上市的產品獲納入，而備受關注的首版商保創新藥目錄亦首次發佈，復星醫藥已上市的CAR-T細胞治療產品奕凱達^®（阿基侖賽注射液）位列其中。這些創新藥在醫保談判中的成功，不僅體現了國家對醫藥創新的支持，也為這些藥物的市場推廣和患者使用提供了有力保障。

復星的創新實力同樣獲得國際藥企的高度認可。12月9日，復星醫藥宣佈其控股子公司與輝瑞簽署許可協議，將口服小分子胰高血糖素樣肽‑1（GLP‑1）受體激動劑（包括 YP05002）及含有該活性成分的產品授予輝瑞於全球範圍及領域獨家開發、使用、生產及商業化權利。

與此同時，復星積極整合全球資源，加速前沿醫療科技在中國落地，提升醫療技術的可及性與普惠性。截至2025年9月底，達芬奇手術機器人已在中國內地及港澳地區370餘家醫院落戶，累計裝機總量超480台，服務患者逾81萬人。

同樣圍繞「健康」這個全球公共議題，在中國鄉村，復星於2017年發起的鄉村醫生項目已累計守護2.5萬名鄉村醫生，惠及300萬戶農村家庭。該項目入選聯合國全球契約組織「二十年二十佳」企業可持續發展案例，成為國際認可的鄉村醫療賦能典範。

積極應對氣候變化，高度重視生物多樣性保護

面對氣候變化這個嚴峻的長期風險，復星深刻認識到全球協作應對這一挑戰的重要性。復星一方面積極響應國家「雙碳」目標，推動碳中和與節能減排，另一方面，已於2021年向社會做出承諾：「力爭於2028年實現碳達峰、2050年實現碳中和」，通過制訂氣候變化緩解和適應策略，支持《巴黎協定》的1.5℃控溫目標。

集團同時積極推動各成員企業開展氣候行動。集團在上海的主要辦公場所－上海地標型建築外灘金融中心（BFC）於2024年成功入選上海市首批碳達峰碳中和試點示範名單，成為示範名單中唯一規模超20萬平方米的大型商業綜合體。

復星在葡萄牙的保險公司Fidelidade，2024年開幕了一個深入研究氣候變化的知識中心，通過與外部實體的合作，包括大學、研究中心、公共機構等，提供氣候變化對社會，尤其是保險行業的影響相關的科學知識。

除了積極應對氣候變化外，復星同時高度重視生物多樣性的保護。復星旅文旗下三亞‧亞特蘭蒂斯失落的空間水族館自2018年開始對海南省及其周邊海域的海龜實施救助、治療。截至2024 年，水族館共救助24隻海龜，開業至今共舉行6次海龜放歸活動，將10隻康復的海龜放歸大海。

11月28日，復星旅文在三亞‧亞特蘭蒂斯舉辦「復星旅文2026產品觀」大會，會上與生態環境部南京環境科學研究所簽署了生物多樣性度假區合作協議。雙方將把生物多樣性保護與棲息地營造融入Club Med 度假村，共同打造全國首個以「人與自然共棲」為核心場景的「生物多樣性度假村」。

全球化與創新，驅動可持續未來

展望未來，復星將繼續深耕主業、加碼創新，堅定推進全球化發展，為股東、員工與社會創造更大價值。同時，復星將持續關注全球可持續發展趨勢，不斷完善ESG管理體系，積極響應國家戰略，保障信息安全，推動科技創新，落實「雙碳」目標，參與公益慈善，保障員工權益，借助復星全球產業生態的資源與優勢，在可持續發展領域創造更大影響力，持續為世界創造美好。

HONG KONG, Dec. 22, 2025 /PRNewswire/ -- CNOOC Limited (the "Company", SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) today announces that Xijiang Oilfields 24 Block Development Project has commenced production.

The project is located in the shallow water of the Pearl River Mouth Basin. The development of the project mainly leverages the adjacent existing facilities of the Huixi Oilfields, with addition of a new unmanned wellhead platform. 10 development wells are planned to be commissioned. The project is expected to achieve a plateau production of approximately 18,000 barrels of oil equivalent per day in 2026. The oil property is light crude.

The new Xijiang 24-7 platform is China's first unmanned offshore platform for high-temperature fluid cooling and export. The temperature control system reduces the impact of high temperatures on subsea pipelines, thereby ensuring stable and continuous production.

CNOOC Limited holds 100% interest in this project and is the operator.

— End —

Notes to Editors:

More information about the Company is available at https://www.cnoocltd.com.

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company's expectations, including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environmental policies, the Company's price forecast, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws and regulations.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: [email protected]

Mr. Cheng Yao
Ever Bloom (HK) Communications Consultants Group Limited
Tel：+852 5540 0725
Fax：+852 2111 1103
Email: [email protected]

香港2025年12月22日 /美通社/ -- 中國海洋石油有限公司（「公司」或「中國海油」，香港聯交所股票代碼：00883（港幣櫃台）及80883（人民幣櫃台），上海證券交易所股票代碼：600938）今天宣佈西江油田群24區開發項目已投產。

該項目位於珠江口盆地淺水，主要依託惠西油田群現有設施開發，新建一座無人井口平台。項目計劃投產生產井10口，預計2026年實現日產約18,000桶油當量的高峰產量，油品性質為輕質原油。

該項目新建的西江24-7平台是中國海上首個油氣水混合物高溫冷卻外輸無人平台，創新溫控系統降低高溫對海底管道的影響，保障油田連續穩產。

中國海油擁有該項目100%的權益，並擔任作業者。

— 完 —

編者注：

如需瞭解中國海洋石油有限公司更多信息，請登錄公司網站https://www.cnoocltd.com

*** *** *** ***

本新聞稿包含公司的前瞻性資料，包括關於本公司和其附屬公司業務相當可能有的未來發展的聲明，例如預期未來事件、業務展望或財務結果。「預期」、「預計」、「繼續」、「估計」、「目標」、「持續」、「可能」、「將會」、「預測」、「應當」、「相信」、「計劃」、「旨在」等詞匯以及相似表達意在判定此類前瞻性聲明。這些聲明以本公司在此日期根據其經驗以及對歷史發展趨勢，目前情況以及預期未來發展的理解，以及本公司目前相信的其它合理因素所做出的假設和分析為基礎。然而，實際結果和發展是否能夠達到本公司的目前預期和預測存在不確定性。實際業績、表現和財務狀況可能與本公司的預期產生重大差異，這些因素包括但不限於宏觀政治及經濟因素、原油和天然氣價格波動有關的因素、石油和天然氣行業高競爭性的本質、氣候變化及環保政策因素、公司價格前瞻性判斷、併購剝離活動、HSSE及保險安排、以及反腐敗反舞弊反洗錢和公司治理相關法規變化。

因此，本新聞稿中所做的所有前瞻性聲明均受這些謹慎性聲明的限制。本公司不能保證預期的業績或發展將會實現，或者即便在很大程度上得以實現，本公司也不能保證其將會對本公司、其業務或經營產生預期的效果。

*** *** *** ***

如有進一步查詢，請聯絡：

劉  翠
媒體/公共關係
中國海洋石油有限公司
電話：+86-10-8452-6641
傳真：+86-10-8452-1441
電郵：[email protected]

程  遙
九富（香港）財訊公關集團有限公司
電話: +852 5540 0725
傳真: +852 2111 1103
電郵：[email protected]

LOS ANGELES, Dec. 20, 2025 /PRNewswire/ -- Mixue, a brand under MIXUE Group (02097.HK), opened its first store in Los Angeles on December 19, marking its debut in the Americas and another step in the group's global expansion strategy.

Located at 6922 Hollywood Blvd Suite 107, the store features Mixue's core menu of ice cream, pure tea, fruit tea, milk tea, and freshly brewed coffee, with customizable sugar levels and toppings. The menu pricing lists the brand's signature ice cream at $1.19, iced lemonade at $1.99, lattes at $2.99, and bubble tea starting at $3.99, with most items priced between $1.19 and $4.99. To mark the opening, Mixue hosted a series of launch activities, including street pop-ups featuring its Snow King mascot, themed photo experiences, and promotional giveaways, attracting strong interest and excitement from local consumers.

Mixue has expanded internationally over several years. The brand opened its first overseas store in Hanoi, Vietnam, in 2018, marking its initial step toward global expansion. Today, Mixue operates approximately 4,700 stores outside China across 13 countries, including Australia, Japan, South Korea, Thailand, Malaysia, and Singapore. The opening of its first store in the United States further extends the brand's global footprint.

MIXUE Group now operates over 53,000 stores worldwide, making it one of the largest freshly made beverage chains by store count. Its rapid expansion and value-focused model have positioned the group ahead of many established global brands in terms of physical footprint. Reflecting its growing international influence, MIXUE Group was included this year in Time magazine's list of the "100 Most Influential Companies in the World," where it was the only restaurant chain recognized. The listing highlights the increasing presence of Chinese consumer brands on the global stage and MIXUE's expanding role in the international food and beverage market.

"Mixue is actively advancing its global strategy. Given the substantial market potential in the United States, the first store serves as a starting point. Moving forward, the company will steadily expand its store footprint, allowing more local consumers to enjoy high-quality, affordable drinks," the head of Mixue U.S. commented at the opening.

By combining applied product research with foundational ingredient and process development, the Company continuously upgrades its core beverage components while introducing freshly made drinks designed to balance quality and affordability. The brand's supply chain is managed through a digital system that supports end-to-end quality control, from ingredient sourcing and production to warehousing and distribution. This "farm-to-table" approach applies consistent standards at each stage. 

Looking ahead, Mixue plans to further expand its presence across the Americas, introducing its value-focused menu to a wider range of consumers. Stores across New York will also begin opening in the coming days. The Company will continue to strengthen its supply chain by expanding sourcing capabilities, improving logistics efficiency, and investing in production capacity and research and development. These efforts are aimed at supporting sustainable growth while maintaining consistent product quality and affordability as Mixue scales in international markets.

For more information about Mixue US, please visit https://www.instagram.com/mixue_global.

About MIXUE Group

Founded in China, MIXUE Group is the world's leading global freshly-made drinks company. Operating the freshly-made tea drinks brand Mixue and freshly-made coffee brand Lucky Cup, Mixue has built a comprehensive end-to-end supply chain at the largest scale in China's freshly-made drinks industry, encompassing essential aspects covering procurement, production, logistics, R&D and quality control. The company is committed to delivering high-quality, affordable fresh beverages to consumers worldwide through its extreme-efficiency global supply chain and franchise model.

Landmark Project Across Four Governorates to Boost Power Plant Output by 50%, Easing Chronic Electricity Shortages

SHANGHAI, Dec. 20, 2025 /PRNewswire/ -- Shanghai Electric has broken ground on the Euphrates Combined Cycle Expansion Project in Iraq. As the project's contractor, Shanghai Electric is upgrading power plants across four Iraqi governorates by transforming simple-cycle units into combined-cycle systems. The expansion will add a total capacity of 625 megawatts (MW) and is designed to boost overall plant efficiency by approximately 50%, generating an additional 5 billion kilowatt-hprojours (kWh) of electricity annually without increasing fuel consumption. This initiative is poised to significantly alleviate the country's persistent electricity shortages.

"The pressing need for energy security and development in Iraq is clear. We are honored that our efficient combined-cycle technology is recognized as instrumental in modernizing this critical infrastructure," said a spokesperson for Shanghai Electric. "This project exemplifies our commitment to supporting the energy security and green development of Belt and Road countries through technological innovation."

Iraq, a major Middle Eastern oil producer, has faced severe power shortages for over three decades. Most of its power plants rely on natural gas, yet domestic gas development lags, creating a heavy dependence on imports. This power deficit has become a persistent challenge to people's livelihoods and a bottleneck for national reconstruction and economic growth.

The Shanghai Electric-contracted expansion project along the Euphrates River broke ground early this year and covers the Iraqi governorates of Najaf, Karbala, Babylon, and Al-Qadisiyyah, with all upgrades centered on advanced combined-cycle technology. Core equipment has now arrived on site, and construction is advancing through the collaboration of Chinese and Iraqi teams. Since its commencement, the project has drawn considerable attention from the Iraqi government and public.

Iraqi Minister of Electricity Ziad Ali Fadel has praised the project's strategic importance, stating, "This initiative is highly significant for improving Iraq's power supply and optimizing its electricity infrastructure. Once operational, it will effectively reduce Iraq's reliance on imported natural gas and lower its fuel costs for power generation."

At the power plant in Najaf, the upgrade utilizes high-temperature exhaust from existing gas turbines as a heat source. The exhaust is directed through heat recovery steam generators to produce high-pressure steam, which then drives a new steam turbine to create additional electricity. This combined-cycle process increases output and efficiency without extra fuel and reduces the thermal pollution from the original units.

Naseem Ayad, the Iraqi project manager at the Najaf site, said, "Chinese equipment and power technology help us reuse high-temperature exhaust, boosting generation capacity while reducing thermal pollution. This project sets a benchmark for power plant upgrades in Iraq and reflects local hopes for more reliable electricity and better living conditions."

At the Karbala site, core equipment such as heat recovery steam generators and direct air-cooled condensers have been delivered. This project phase marks one of Iraq's first combined-cycle expansions to fully utilize Chinese equipment and standards, with core systems designed and manufactured in China. This will effectively drive the overseas deployment of Chinese equipment and enhance the recognition of Chinese standards in Iraq.

Upon completion, the project is expected to improve local livelihoods, support post-war reconstruction, and lay a robust energy foundation for Iraq's industrial recovery and economic growth.

Shanghai Electric remains dedicated to supporting sustainable development in Belt and Road regions and worldwide through advanced, efficient, and eco-friendly energy technologies.

For more information, please visit https://www.shanghai-electric.com/group_en/.

SHANGHAI, Dec. 19, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK) announced that it has been named to the CDP "A" lists for both Climate Change and Water Security for 2025, underscoring its leadership in environmental stewardship and transparent disclosure.

Climate Change Leadership

Being recognized with an "A" rating by CDP for Climate Change affirms WuXi Biologics' leadership in environmental performance. The company's integrated climate change strategy – which has been validated by SBTi – is anchored in a clear goal of achieving net-zero emissions across its value chain by 2050. To reach this goal, the company has developed a refined roadmap and implemented robust initiatives, including energy efficiency programs, process optimization, and renewable energy adoption. Notably, its biologics facility in Ireland now operates on 100% renewable electricity.

Water Security Excellence

For the third consecutive year, WuXi Biologics has earned a place on the CDP Water Security "A" List. The company has established a comprehensive framework for water management – aligned with United Nations SDG 6 – and set a clear target to reduce water consumption intensity by 30% by the end of 2025 compared to the 2019 baseline. Reaffirming its dedication to good water stewardship and commitment to sustainable water management, the company launched a Water Excellence Stewardship (WES) program that covers such material topics as water governance, water balance, water quality, and safe water/environmental and personal hygiene (WASH).

Earlier this year, WuXi Biologics was also recognized with an "A" rating in the CDP's Supplier Engagement assessment for its efforts in driving climate action across the value chain. While working to advance its own climate goals, the company actively collaborates with global suppliers to accelerate the transition toward a net-zero and sustainable economy through a comprehensive sustainable supply chain management system, Scope 3 emissions disclosure and target progress tracking.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are deeply honored to receive these 'A' ratings from CDP, reflecting our commitment to Climate Change and Water Security. This recognition bolsters our resolve – as a global leader in green biologics CRDMO – to drive the industry toward a more responsible and sustainable future."

As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

ESG
[email protected]

Media
[email protected]

香港2025年12月19日 /美通社/ -- 由復星財富國際控股有限公司（簡稱「復星財富控股」）與星路金融科技控股有限公司（簡稱「星路科技」）主辦、泰康資產管理（香港）有限公司（簡稱「泰康資管（香港）」）協辦的「Web5生態：引領全球財富管理新時代」峰會於香港舉辦。峰會上，星路科技重磅發佈其升級版一站式RWA（Real World Assets，現實世界資產）技術、發行及分銷平台——FinRWA Platform 2.0（簡稱「FRP 2.0」），推動構建更加開放、融合、合規、創新的金融生態。

貫徹Web5戰略，推動融合與合規並進

本次峰會雲集了來自Web3基礎設施、金融科技、數字資產等領域逾200位行業領袖，圍繞資產上鏈、技術合規與生態共建等前沿議題展開深度交流。香港特別行政區政府財經事務及庫務局副局長陳浩濂太平紳士為活動發表視頻致辭，香港特別行政區立法會議員（科技創新界）邱達根先生、香港數碼港管理有限公司首席企業發展官朱美恩女士出席並致辭演講。

復星財富控股行政總裁、星路科技董事長程康先生在開幕致辭中表示，為積極響應香港特區政府《香港數字資產發展政策宣言2.0》及金管局「金融科技2030」DART戰略，復星財富控股與星路科技積極推動財富管理行業的數字化升級與可持續發展，構建開放協同的Web5（Web2+Web3）生態。復星財富控股作為全球一站式Web5財富管理平台，擁有深厚的財富管理與數字資產服務經驗；旗下星路科技作為一站式Web5財富科技平台，已成為香港首家支持多幣種代幣化基金分銷的平台，並成功構建香港首個單位信托架構代幣化基金技術解決方案，在香港乃至亞洲的RWA領域實現多項行業突破。「2026年將是融合之年、突破之年、生態之年。我們期待見證更多機構與個人跨越數字鴻溝，擁抱Web5帶來的財富管理新範式。復星財富控股與星路科技將持續通過數字化創新，助力傳統金融接入Web3新興生態，攜手各界夥伴共同推動財富管理行業邁向更加開放、融合、合規的Web5未來。」

FRP 2.0：新一代RWA代幣化協同平台

星路科技CEO蔡華先生於峰會發佈了星路科技一站式RWA技術、發行及分銷平台的升級版——FinRWA Platform 2.0（簡稱「FRP 2.0」）。FRP 2.0致力於構建新一代RWA代幣化協同平台，以合規為基石、協作為引擎、透明為保障，助力不同機構實現合規發行，重塑數字資產管理流程。FRP2.0具備全球化、高相容性的分銷網路，通過整合Web2的合規框架與Web3的技術效率，已打通香港持牌虛擬資產交易所、傳統券商及銀行渠道，支持多幣種代幣化基金的分銷。相較上一代系統，FRP 2.0在功能、效能與安全性上均實現顯著提升。

該平台引入代幣化服務（Tokenization as a Service, TaaS），為公募、私募基金等金融資產的上鏈提供更清晰、更合規的操作路徑，主要亮點包括：

• 跨機構業務協同：平台支持發行人、托管方、代幣代理人等多種機構共同參與代幣化全生命周期管理，實現數據互聯互通。
• 精細化權限體系：遵循最小權限原則，管理員可基於角色勾選功能模塊；操作界面做隔離設計，從源頭杜絕越權操作。
• 靈活審批流程：審批流程可高度自定義。操作流程全程留痕，支持事後審計與回溯；業務進行中系統自動完成KYT（了解你的交易）合規性校驗，並將結果即時回饋，為業務安全保駕護航。
• 資產透明化管理：數據與區塊鏈同步，可實時查看代幣合約詳情、交易哈希等；支持歷史價格波動分析和分紅記錄管理，為資產估值提供可靠依據。

蔡華表示，「FRP 2.0致力於推動生態互聯，打破機構間數據壁壘，助力構建香港Web3.0創新樞紐，促進更開放的金融協作生態。我們希望以領先的代幣化基礎設施，將萬億級實體資產轉化為鏈上數字機遇。」

此外，蔡華亦介紹了星路科技在AI技術領域的前沿突破，貫通客戶觸達、產品盡調、投研決策等關鍵環節。例如產品盡調方面，星路科技的AI KYP Writer可以以99%的準確率、1分鐘完成原需半天生成的金融盡調與風控報告，節省80%人力成本，助力新品極速上線，以科技創新驅動財富管理模式持續升級。

本次峰會還設置了兩場圓桌論壇，分別以《2026年香港Web2+Web3發展潛力和機會》、《打通合規Web2+Web3，支持香港Web3.0發展》為主題，邀請了來自Bybit、Solana 基金會、FOMO Pay、Conflux、君合律師事務所、OSL、泰康資管（香港）及Matrixport的前沿代表人物共同探討Web5生態的創新實踐。

關於復星財富國際控股有限公司

復星財富國際控股有限公司及其子公司統稱「復星財富控股」，是復星國際（股票代號：656.HK）在港全資控股的AI驅動全球一站式Web5財富管理平台。復星財富控股資本實力雄厚，旗下各子公司分別持有香港證監會頒發的第1、2、4、6、9類牌照及香港保監局的保險經紀牌照。在Web3浪潮下，復星財富控股旗下全資子公司復星國際證券有限公司於2024年6月取得香港證監會1號牌升級，旗下全資子公司復星國際資產管理有限公司已取得香港證監會4號及9號牌的升級，積極探索虛擬資產業務。

關於星路金融科技控股有限公司

星路金融科技控股有限公司及其子公司統稱「星路科技」，是復星財富控股自主孵化的AI驅動全球一站式Web5財富科技平台，為各類金融機構提供全面的財富管理產品和科技解決方案，涵蓋現金管理、公募基金、私募基金、結構性產品、債券、保險及虛擬資產等全品類的財富管理產品。星路科技在亞洲金融科技領域處於領先地位，自Web3浪潮初起，星路科技已專注提升連接實體與數字資產的能力，打造一站式現實世界資產（RWA）技術、發行、分銷平台，開拓財富管理行業全新增長路徑。

香港2025年12月19日 /美通社/ -- 由復星財富國際控股有限公司（簡稱「復星財富控股」）與星路金融科技控股有限公司（簡稱「星路科技」）主辦、泰康資產管理（香港）有限公司（簡稱「泰康資管（香港）」）協辦的「Web5生態：引領全球財富管理新時代」峰會於香港舉辦。峰會上，星路科技重磅發佈其升級版一站式RWA（Real World Assets，現實世界資產）技術、發行及分銷平台——FinRWA Platform 2.0（簡稱「FRP 2.0」），推動構建更加開放、融合、合規、創新的金融生態。

貫徹Web5戰略，推動融合與合規並進

本次峰會雲集了來自Web3基礎設施、金融科技、數字資產等領域逾200位行業領袖，圍繞資產上鏈、技術合規與生態共建等前沿議題展開深度交流。香港特別行政區政府財經事務及庫務局副局長陳浩濂太平紳士為活動發表視頻致辭，香港特別行政區立法會議員（科技創新界）邱達根先生、香港數碼港管理有限公司首席企業發展官朱美恩女士出席並致辭演講。

復星財富控股行政總裁、星路科技董事長程康先生在開幕致辭中表示，為積極響應香港特區政府《香港數字資產發展政策宣言2.0》及金管局「金融科技2030」DART戰略，復星財富控股與星路科技積極推動財富管理行業的數字化升級與可持續發展，構建開放協同的Web5（Web2+Web3）生態。復星財富控股作為全球一站式Web5財富管理平台，擁有深厚的財富管理與數字資產服務經驗；旗下星路科技作為一站式Web5財富科技平台，已成為香港首家支持多幣種代幣化基金分銷的平台，並成功構建香港首個單位信托架構代幣化基金技術解決方案，在香港乃至亞洲的RWA領域實現多項行業突破。「2026年將是融合之年、突破之年、生態之年。我們期待見證更多機構與個人跨越數字鴻溝，擁抱Web5帶來的財富管理新範式。復星財富控股與星路科技將持續通過數字化創新，助力傳統金融接入Web3新興生態，攜手各界夥伴共同推動財富管理行業邁向更加開放、融合、合規的Web5未來。」

FRP 2.0：新一代RWA代幣化協同平台

星路科技CEO蔡華先生於峰會發佈了星路科技一站式RWA技術、發行及分銷平台的升級版——FinRWA Platform 2.0（簡稱「FRP 2.0」）。FRP 2.0致力於構建新一代RWA代幣化協同平台，以合規為基石、協作為引擎、透明為保障，助力不同機構實現合規發行，重塑數字資產管理流程。FRP2.0具備全球化、高相容性的分銷網路，通過整合Web2的合規框架與Web3的技術效率，已打通香港持牌虛擬資產交易所、傳統券商及銀行渠道，支持多幣種代幣化基金的分銷。相較上一代系統，FRP 2.0在功能、效能與安全性上均實現顯著提升。

該平台引入代幣化服務（Tokenization as a Service, TaaS），為公募、私募基金等金融資產的上鏈提供更清晰、更合規的操作路徑，主要亮點包括：

• 跨機構業務協同：平台支持發行人、托管方、代幣代理人等多種機構共同參與代幣化全生命周期管理，實現數據互聯互通。
• 精細化權限體系：遵循最小權限原則，管理員可基於角色勾選功能模塊；操作界面做隔離設計，從源頭杜絕越權操作。
• 靈活審批流程：審批流程可高度自定義。操作流程全程留痕，支持事後審計與回溯；業務進行中系統自動完成KYT（了解你的交易）合規性校驗，並將結果即時回饋，為業務安全保駕護航。
• 資產透明化管理：數據與區塊鏈同步，可實時查看代幣合約詳情、交易哈希等；支持歷史價格波動分析和分紅記錄管理，為資產估值提供可靠依據。

蔡華表示，「FRP 2.0致力於推動生態互聯，打破機構間數據壁壘，助力構建香港Web3.0創新樞紐，促進更開放的金融協作生態。我們希望以領先的代幣化基礎設施，將萬億級實體資產轉化為鏈上數字機遇。」

此外，蔡華亦介紹了星路科技在AI技術領域的前沿突破，貫通客戶觸達、產品盡調、投研決策等關鍵環節。例如產品盡調方面，星路科技的AI KYP Writer可以以99%的準確率、1分鐘完成原需半天生成的金融盡調與風控報告，節省80%人力成本，助力新品極速上線，以科技創新驅動財富管理模式持續升級。

本次峰會還設置了兩場圓桌論壇，分別以《2026年香港Web2+Web3發展潛力和機會》、《打通合規Web2+Web3，支持香港Web3.0發展》為主題，邀請了來自Bybit、Solana 基金會、FOMO Pay、Conflux、君合律師事務所、OSL、泰康資管（香港）及Matrixport的前沿代表人物共同探討Web5生態的創新實踐。

關於復星財富國際控股有限公司

復星財富國際控股有限公司及其子公司統稱「復星財富控股」，是復星國際（股票代號：656.HK）在港全資控股的AI驅動全球一站式Web5財富管理平台。復星財富控股資本實力雄厚，旗下各子公司分別持有香港證監會頒發的第1、2、4、6、9類牌照及香港保監局的保險經紀牌照。在Web3浪潮下，復星財富控股旗下全資子公司復星國際證券有限公司於2024年6月取得香港證監會1號牌升級，旗下全資子公司復星國際資產管理有限公司已取得香港證監會4號及9號牌的升級，積極探索虛擬資產業務。

關於星路金融科技控股有限公司

星路金融科技控股有限公司及其子公司統稱「星路科技」，是復星財富控股自主孵化的AI驅動全球一站式Web5財富科技平台，為各類金融機構提供全面的財富管理產品和科技解決方案，涵蓋現金管理、公募基金、私募基金、結構性產品、債券、保險及虛擬資產等全品類的財富管理產品。星路科技在亞洲金融科技領域處於領先地位，自Web3浪潮初起，星路科技已專注提升連接實體與數字資產的能力，打造一站式現實世界資產（RWA）技術、發行、分銷平台，開拓財富管理行業全新增長路徑。

The US government has begun the approval process for Nvidia (NVDA.US) to export its H200 chips to China, Reuters quoted sources as saying.

The US Department of Commerce has submitted the chip export license application to the State Department, Department of Energy and Department of Defense for review.

It is believed that these departments have 30 days to conduct their evaluations, and US President Donald Trump will have the right of final decision.
~

AASTOCKS Financial News
Website: www.aastocks.com